⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3935267 | 0.69 | — | — | |
| SCHEMBL12186114 | 0.62 | — | — | |
| SCHEMBL878822 | 0.62 | — | — | |
| SCHEMBL826097 | 0.60 | — | — | |
| SCHEMBL10964925 | 0.60 | — | — | |
| SCHEMBL10997116 | 0.59 | — | — | |
| SCHEMBL11305752 | 0.56 | — | — | |
| SCHEMBL10681974 | 0.55 | SIGMAR1 (0.36) | — | |
| SCHEMBL4947252 | 0.55 | — | — | |
| SCHEMBL14327682 | 0.53 | TRPA1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6066737-A | Process for the preparation of optically enriched 4-aryl-3-hydromethyl substituted piperidines to be used as intermediates in the synthesis of paroxetine | CHIROTECH TECHNOLOGY, LTD. (GB) | 2000-05-23 | — | — | US | claimed |
| US-5420142-A | FOR TREATMENT OF CARDIOVASCULAR CONDITIONS WHICH REQUIRE AN INCREASE IN CONTRACTILITY OF THE HEART | BAYER AKTIENGESELLSCHAFT (DE) | 1995-05-30 | — | — | US | claimed |
| EP-0518105-A1 | 3-Formyl-1,4-dihydropyridines, process for their preparation and their pharmaceutical use | BAYER AG (DE) | 1992-12-16 | — | — | EP | claimed |
| CN-110114356-B | Benzodiazepine derivatives having activity on the central nervous system and the vascular system | 哈瓦那大学 | 2021-09-24 | — | — | CN | disclosed |
| CN-107987131-A | One group of compound, its preparation method and application with anti-drug resistance bacterial activity | 上海来益生物药物研究开发中心有限责任公司 | 2018-05-04 | — | — | CN | disclosed |
| WO-2008058234-A2 | PHARMACEUTICAL FORMULATIONS FOR 1,4-DIHYRDROPYRIDINE COMPOUNDS HAVING IMPROVED SOLUBILITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-05-15 | — | — | WO | disclosed |
| US-6066737-A | Process for the preparation of optically enriched 4-aryl-3-hydromethyl substituted piperidines to be used as intermediates in the synthesis of paroxetine | CHIROTECH TECHNOLOGY, LTD. (GB) | 2000-05-23 | — | — | US | disclosed |
| US-6066737-A | Process for the preparation of optically enriched 4-aryl-3-hydromethyl substituted piperidines to be used as intermediates in the synthesis of paroxetine | CHIROTECH TECHNOLOGY, LTD. (GB) | 2000-05-23 | — | — | US | disclosed |
| EP-0874820-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ENRICHED 4-ARYL-3-HYDROMETHYL SUBSTITUTED PIPERIDINES TO BE USED AS INTERMEDIATES IN THE SYNTHESIS OF PAROXETINE | Chirotech Technology Limited (GB) | 1998-11-04 | — | — | EP | disclosed |
| EP-0874820-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ENRICHED 4-ARYL-3-HYDROMETHYL SUBSTITUTED PIPERIDINES TO BE USED AS INTERMEDIATES IN THE SYNTHESIS OF PAROXETINE | Chirotech Technology Limited (GB) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997024323-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ENRICHED 4-ARYL-3-HYDROMETHYL SUBSTITUTED PIPERIDINES TO BE USED AS INTERMEDIATES IN THE SYNTHESIS OF PAROXETINE | CHIROTECH TECHNOLOGY (GB) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997024323-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ENRICHED 4-ARYL-3-HYDROMETHYL SUBSTITUTED PIPERIDINES TO BE USED AS INTERMEDIATES IN THE SYNTHESIS OF PAROXETINE | CHIROTECH TECHNOLOGY (GB) | 1997-07-10 | — | — | WO | disclosed |
| US-5420142-A | FOR TREATMENT OF CARDIOVASCULAR CONDITIONS WHICH REQUIRE AN INCREASE IN CONTRACTILITY OF THE HEART | BAYER AKTIENGESELLSCHAFT (DE) | 1995-05-30 | — | — | US | disclosed |
| US-5420142-A | FOR TREATMENT OF CARDIOVASCULAR CONDITIONS WHICH REQUIRE AN INCREASE IN CONTRACTILITY OF THE HEART | BAYER AKTIENGESELLSCHAFT (DE) | 1995-05-30 | — | — | US | disclosed |
| US-5420142-A | FOR TREATMENT OF CARDIOVASCULAR CONDITIONS WHICH REQUIRE AN INCREASE IN CONTRACTILITY OF THE HEART | BAYER AKTIENGESELLSCHAFT (DE) | 1995-05-30 | — | — | US | disclosed |
| EP-0540625-A1 | NOVEL SPIRO-ISOXAZOLIDINE DERIVATIVES AS CHOLINERGIC AGENTS | FISONS CORPORATION (US) | 1993-05-12 | — | — | EP | disclosed |
| EP-0518105-A1 | 3-Formyl-1,4-dihydropyridines, process for their preparation and their pharmaceutical use | BAYER AG (DE) | 1992-12-16 | — | — | EP | disclosed |
| EP-0518105-A1 | 3-Formyl-1,4-dihydropyridines, process for their preparation and their pharmaceutical use | BAYER AG (DE) | 1992-12-16 | — | — | EP | disclosed |
| EP-0518105-A1 | 3-Formyl-1,4-dihydropyridines, process for their preparation and their pharmaceutical use | BAYER AG (DE) | 1992-12-16 | — | — | EP | disclosed |
| WO-1992001690-A1 | NOVEL SPIRO-ISOXAZOLIDINE DERIVATIVES AS CHOLINERGIC AGENTS | FISONS CORPORATION (US) | 1992-02-06 | — | — | WO | disclosed |